TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00700791

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol supplement (TCT)
Description: Oral Vitamin E Tocotrienol Supplement (TCT)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol supplement (TCT)
Description: Oral Vitamin E Tocotrienol Supplement (TCT)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol supplement (TCT)
Description: Oral Vitamin E Tocotrienol Supplement (TCT)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol supplement (TCT)
Description: Oral Vitamin E Tocotrienol Supplement (TCT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol Cream (TCT)
Description: Natural Vitamin E Tocotrienol(TCT)Topical Cream

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol Cream (TCT)
Description: Natural Vitamin E Tocotrienol(TCT)Topical Cream

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol Cream (TCT)
Description: Natural Vitamin E Tocotrienol(TCT)Topical Cream

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol Cream (TCT)
Description: Natural Vitamin E Tocotrienol(TCT)Topical Cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study: NCT02459756

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
Study: NCT00700791

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topical Placebo Cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topical Placebo Cream

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cream
Description: Topical Placebo Cream

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cream
Description: Topical Placebo Cream
Study: NCT00901940

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W-135) Conjugate
Description: 2 x 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide A, C, Y and W135 and Menveo
Description: 1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
Study: NCT04155775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer electronic health record alert (Best Practice Alert - BPA)
Description: Upon ordering platelets in patients with recent platelet count \>50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
Study: NCT00175903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine Controlled Release (CBZ-CR)
Description: Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate Extended Release
Description: Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
Study: NCT01948375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real needle- placebo needle
Description: All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo needle - real needle
Description: All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
Study: NCT03392636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Herniotomy
Description: In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Herniotomy
Description: In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
Study: NCT06390475

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Direct Thrombus Imaging (MRDTI)
Description: Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Direct Thrombus Imaging (MRDTI)
Description: Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.
Study: NCT00494494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: topical antibiotic for 10 days plus topical corticosteroids for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nepafenac
Description: liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
Study: NCT00290511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
Study: NCT04226079

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of exhaled breath
Description: Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of exhaled breath
Description: Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
Study: NCT01367808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given placebo twice a day for 5 days prior to the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vorikonazole
Description: The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: posakonazole
Description: The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
Study: NCT03364049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7162
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7162
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7162
Description: oral tablets
Study: NCT04088812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo meat derivative + Placebo satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo meat derivative + Satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
Study: NCT03364049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7162
Description: oral tablets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT04088812

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo meat derivative + Satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo meat derivative + Satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
Study: NCT03364049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT02343510

Intervention type: OTHER
Intervention: PCR for chlamydia DNA in primary tubal cancer
Description: PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
Study: NCT04088812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental meat derivative + Placebo satiating control
Description: Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental meat derivative + Placebo satiating control
Description: Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
Study: NCT00290511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 IV over 5-30 minutes on Day 2.
Study: NCT02343510

Intervention type: OTHER
Intervention: PCR for chlamydia DNA in primary tubal cancer
Description: PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups

Intervention type: OTHER
Intervention: PCR for chlamydia DNA in primary tubal cancer
Description: PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups

Intervention type: OTHER
Intervention: PCR for chlamydia DNA in primary tubal cancer
Description: PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
Study: NCT02111616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan (SCP)
Description: Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Care Plan (SCP)
Description: Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated PCP visit
Description: Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
Study: NCT00290511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: 0.3 mCi/kg IV after 4 cycles of R-FND.
Study: NCT04483440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-110
Description: 4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-110
Description: 4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-110
Description: 4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
Study: NCT00290511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg by mouth (PO) or IV daily on Days 2-6.
Study: NCT00544713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose and Glycerin based artificial tear
Description: As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose
Description: As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
Study: NCT02511587

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-Immune vaccination
Description: booster vaccination with FSME-Immune

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME-Immune vaccination
Description: booster vaccination with FSME-Immune
Study: NCT01927250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Okada Health and Wellness program
Description: Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
Study: NCT01655836

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo high dose rate brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study: NCT03592641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Given PO
Study: NCT02465528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378)
Description: Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378)
Description: Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378)
Description: Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378)
Description: Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
Study: NCT02214147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib will be supplied as enteric coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib will be supplied as enteric coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib will be supplied as enteric coated tablets.
Study: NCT00354224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02361567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramacet
Description: Pain medication commonly used post-operatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet
Description: Pain medication commonly used post-operatively
Study: NCT02247349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)
Study: NCT04480502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: PD-L1 single domain antibody for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: PD-L1 single domain antibody for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: PD-L1 single domain antibody for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: PD-L1 single domain antibody for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: CTLA-4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: CTLA-4 monoclonal antibody
Study: NCT00609115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES device (test)
Description: Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AMES device (sham)
Description: Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMES device (crossover)
Description: Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
Study: NCT02248428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500mg orally daily on days 1-28,repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally weekly on days 1,8,15,22,repeated every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg orally weekly on days 1,8,15,22,repeated every 28 days
Study: NCT03254407

Intervention type: OTHER
Group type: OTHER
Intervention: Screening medical record
Description: Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
Study: NCT02682069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MolecuLight i:X Imaging Device
Description: The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
Study: NCT00755573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 300 mg - 600 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Regime as described for pregabalin